Joana Goncalves Sells 7,000 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) insider Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $32.37, for a total value of $226,590.00. Following the completion of the sale, the insider owned 34,018 shares in the company, valued at approximately $1,101,162.66. The trade was a 17.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Joana Goncalves also recently made the following trade(s):

• On Thursday, January 15th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $31.81, for a total value of $222,670.00.
• On Friday, December 19th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $30.61, for a total value of $214,270.00.

Oruka Therapeutics Stock Performance

Shares of ORKA opened at $32.27 on Thursday. The stock has a 50 day moving average price of $31.66 and a 200 day moving average price of $25.27. Oruka Therapeutics, Inc. has a one year low of $5.49 and a one year high of $36.51. The stock has a market capitalization of $1.56 billion, a price-to-earnings ratio of -16.98 and a beta of -0.38.

Analyst Ratings Changes

Several research firms have recently weighed in on ORKA. Wedbush raised their price target on shares of Oruka Therapeutics from $42.00 to $45.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. Guggenheim assumed coverage on Oruka Therapeutics in a report on Monday, October 27th. They set a “buy” rating and a $60.00 target price on the stock. Wall Street Zen cut Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, November 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Thursday, January 22nd. Finally, HC Wainwright dropped their target price on Oruka Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a report on Monday, October 27th. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Oruka Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $54.50.

Hedge Funds Weigh In On Oruka Therapeutics

Several large investors have recently modified their holdings of the business. Viking Global Investors LP acquired a new stake in shares of Oruka Therapeutics during the 3rd quarter worth about $51,280,000. Paradigm Biocapital Advisors LP acquired a new stake in shares of Oruka Therapeutics during the fourth quarter valued at about $51,840,000. Remedium Capital Partners LLC purchased a new stake in shares of Oruka Therapeutics in the 4th quarter valued at approximately $47,054,000. Avoro Capital Advisors LLC purchased a new stake in shares of Oruka Therapeutics in the 3rd quarter valued at approximately $25,640,000. Finally, Deep Track Capital LP lifted its holdings in shares of Oruka Therapeutics by 38.4% in the 3rd quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock worth $51,051,000 after acquiring an additional 735,983 shares during the last quarter. Institutional investors and hedge funds own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.